Siegfried AG • Untere Brühlstrasse 4, 4800 Zofingen, Switzerland
Phone: + 41 62 746 1111 • Fax: + 41 62 746 1202
Web: www.siegfried.ch • E-mail: firstname.lastname@example.org
Year Founded: 1873
Number of Employees: 2300
Annual Worldwide Revenues: 700 Mio CHF
Key Personnel: Rudolf Hanko, Ph.D., Chief Executive Officer;
Rene Imwinkelried, Ph.D., Head Technical Operations, Head
Science and Development; Marianne Späne, Head Business
Development & Sales; Wolfgang Wienand, Head Strategy and
Mergers & Acquisitions; Peter Kiechle, Ph.D., Compliance
Expect more with Siegfried as your preferred partner
Siegfried provides both drug substance and drug product
development together with production capabilities at various
facilities worldwide. As a partner of Siegfried, you profit from a
broad range of technical capabilities and capacities along the
value-chain. Creating and manufacturing formulations is our
passion. You can expect from Siegfried relevant expertise & know-how at each step of your project, coupled with a keen enthusiasm.
As a leading integrated drug substance and drug product provider,
our professionalism is pivotal for your project throughout
the entire life cycle. Having such a combination of know-how
and experience is unique for a supplier of development and
Drug Substances: Custom development and Contract
Manufacturing services for both API and intermediates and, also
we offer our own portfolio of API (opiates and other controlled
substances) as well as dossiers with independent patented
Drug Products: Our clients benefit from a broad base of know-how
in complex oral drug delivery systems including sterile filling, with
in-house development, customer development and manufacturing,
as well as a portfolio of finished dosage form products.
Chemical synthesis & product formulation under one roof
Improving chemical processes and formulations is our passion.
For custom synthesis, we offer a variety of special technologies,
e.g. CTF, hydrogenation, azide chemistry and phosgenation,
high pressure reactions and handling halogens (CI/Br/I). We
work closely with customers to develop and optimize innovative
chemical processes. Also, we have high containment capabilities
with complex bridging technologies such as spray drying, which
add more benefit and value to our customers. In addition,
proprietary portfolios of drugs are available for licensing and nonexclusive sales that focus on opiate base and addiction treatment.
Siegfried also offers complex oral drug delivery systems with in-house developments for licensing. Projects range from formulation,
narcotics, high potency active pharmaceutical ingredients, robust
manufacturing processes and application of new technologies.
Additionally, we are well experienced in developing second and third
generation formulations to support product life-cycle management.
Siegfried has worldwide presence with chemical manufacturing multipurpose cGMP sites located in Zofingen, Switzerland, Pennsville, New
Jersey USA; Nantong, China; Minden Germany, Saint-Vulbas France,
and Evionnaz Switzerland; and with also drug product manufacturing
sites in Zofingen, Switzerland (Pilot); Malta, Irvine USA and Hameln,
Germany. Compliance is a top priority at Siegfried. We adhere to the
most rigorous requirements and quality guidelines possible; thus, we
continue to maintain an outstanding track record by both regulatory
authorities and our customers.